Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9-12 March 2026:

EMA’s safety committee (PRAC) has reviewed new safety information with chikungunya vaccine Ixchiq and has recommended an update to the vaccine’s product information to reflect the most recent evidence related to this known risk.

The safety signal was started following a reported case of aseptic meningitis which occurred in a healthy young adult following vaccination with Ixchiq. Ixchiq’s product information will now be updated to reflect that serious side effects, such as aseptic meningitis, have also been observed in healthy young adults. Previously, most reported cases had occurred in older people (over 65 years of age) or people with multiple long-term medical conditions.